Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Question
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Direct answer
Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline. — bullish pressure on MESO.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-27
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial”, revision 1, evidence through 2026-08-27. https://marketontology.com/catalysts/2026-08-27/mesoblast-delivers-120-3m-fy26-revenue-and-concludes-phase-3-back-pain-trial-2f0ff3
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| MESO | ▲Bull | 1–4 weeks | Catalyst Driven | 72 |
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline. — bullish pressure on MESO.
Mesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.
- SummaryMesoblast reported fiscal 2026 revenue of US$120.3 million, marking a transition to commercial-stage biotechnology operations. Product sales were driven almost entirely by RYONCIL, which contributed US$115.2 million. In clinical development, Mesoblast confirmed the completion of patient treatment in its pivotal Phase 3 study of rexlemestrocel-L for chronic low back pain, setting up prospective readouts for its cellular therapy pipeline.
- MESODirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MESO closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MESO price vs. pre-event level
- MESO volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-08-27Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial LaunchMESO
- 2026-08-27Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain TrialMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for RyoncilMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESOMESO
- 2026-07-30Mesoblast Reports $115M First-Year Revenue for Ryoncil → Bullish MESO → Bullish MESOMESO
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.